What is the official ID of this bill?
The official print number for this legislation is HR 2343.
Home Treatment for Alpha-1 Antitrypsin Deficiency: New Medicare Rules
This new act aims to make it easier for individuals with Alpha-1 Antitrypsin Deficiency to receive treatment at home under Medicare. This means patients can get necessary infusion therapies in the comfort of their own homes, potentially improving their quality of life and reducing the burden of medical facility visits. The act also establishes payment rules for infusion kits and nursing services.
Key points
Medicare will cover the costs of Alpha-1 Antitrypsin Deficiency treatment (augmentation therapy) administered at home.
Payments will include intravenous administration kits and up to 2 hours of nursing services provided at home by qualified suppliers.
The changes will take effect on January 1, 2027, and apply to individuals enrolled in both Medicare Parts A and B who are not in a Medicare Advantage plan.
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.